• Viking Therapeutics flagged new clinical updates for VK2735, its dual GLP-1/GIP agonist being developed in oral and subcutaneous forms for obesity and related metabolic disorders.
• Data from 13-week Phase 2 VENTURE-Oral trial have not yet been presented, with results slated for poster display at European Congress on Obesity in Istanbul on May 12-15, 2026.
• Poster highlights point to meaningful weight-loss outcomes with oral VK2735, with tolerability assessed over study duration, without disclosing detailed performance figures.
• Separate ECO poster will outline design and enrollment profile for ongoing Phase 3 VANQUISH-1 study of subcutaneous VK2735 in adults with obesity or overweight with at least one weight-related comorbidity.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA51087) on May 05, 2026, and is solely responsible for the information contained therein.